Xenetic Biosciences, Inc. (XBIO) Hits New 52-Week Low at $1.84
Xenetic Biosciences, Inc. (NASDAQ:XBIO)’s share price hit a new 52-week low on Monday . The company traded as low as $1.84 and last traded at $1.84, with a volume of 16,608 shares. The stock had previously closed at $2.02.
Separately, Zacks Investment Research raised Xenetic Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, July 13th.
The firm has a 50-day moving average of $2.47 and a 200-day moving average of $2.47. The firm’s market cap is $29.55 million.
Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings results on Monday, August 14th. The company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.13). Equities analysts expect that Xenetic Biosciences, Inc. will post ($0.89) EPS for the current year.
TRADEMARK VIOLATION WARNING: This story was reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.watchlistnews.com/xenetic-biosciences-inc-xbio-hits-new-52-week-low-at-1-84/1606410.html.
Xenetic Biosciences Company Profile
Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.
Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.